Socioeconomic inequality in the use of prescription medications for smoking cessation among patients with COPD: A nationwide study

International Journal of COPD

Volumn 13, Issue , 2018, Pages 1775-1781

  Tøttenborg, Sandra Søgaard ^a   Clark, Alice Jessie ^a   Thomsen, Reimar Wernich ^b   Johnsen, Søren Paaske ^b   Lange, Peter ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Bupropion; Lung disease; Smoking intervention; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHABITATION; COHABITING PERSON; CONSULTATION; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; EDUCATION; ETHNICITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HIGHEST INCOME GROUP; HUMAN; INCOME; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; SMOKING; SMOKING CESSATION; SOCIOECONOMICS; TREATMENT DURATION; AGE; DRUG THERAPY; MIDDLE AGED; REGRESSION ANALYSIS; SEX FACTOR;

ADULT; AGE FACTORS; AGED; BUPROPION; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; SEX FACTORS; SMOKING; SMOKING CESSATION; SMOKING CESSATION AGENTS; SOCIOECONOMIC FACTORS; VARENICLINE;

EID: 85048282327     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S158954     Document Type: Article

References (34)

1. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23(3):464-476.
2. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999; 106(4):410-416.
3. Godtfredsen NS, Lam TH, Hansel TT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32(4):844-853.
4. Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24(4):457-463.
5. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002;57(11):967-972.
6. Kupiainen H, Kinnula VL, Lindqvist A, et al. Successful smoking cessation in COPD: association with comorbidities and mortality. Pulm Med. 2012;2012:725024.
7. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233-239.
8. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857-866.
9. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-1294.
10. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
11. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
12. Tøttenborg SS, Thomsen RW, Nielsen H, Johnsen SP, Frausing Hansen E, Lange P. Improving quality of care among COPD outpatients in Denmark 2008-2011. Clin Respir J. 2013;7(4):319-327.
13. Tøttenborg SS, Thomsen RW, Johnsen SP, Nielsen H, Lange P. Determinants of smoking cessation in COPD patients treated in the outpatient setting. Chest. 2016;150(3):554-562.
14. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119(5):1365-1370.
15. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.
16. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357(9268):1571-1575.
17. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(19):2286-2292.
18. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037): 2507-2520.
19. Lange P, Tøttenborg SS, Sorknes AD, et al. Danish register of chronic obstructive pulmondary disease. Clin Epidemiol. 2016;8:1-6.
20. Kildemoes HW, Sorensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39(7 Suppl):38-41.
21. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975-981.
22. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48.
23. Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014. Clin Epidemiol. 2016;8: 381-387.
24. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5 (Suppl 1):3-29.
25. McKee SA, O’Malley SS, Salovey P, Krishnan-Sarin S, Mazure CM. Perceived risks and benefits of smoking cessation: gender-specific predictors of motivation and treatment outcome. Addict Behav. 2005; 30(3):423-435.
26. Abrams DB, Monti PM, Pinto RP, Elder JP, Brown RA, Jacobus SI. Psychosocial stress and coping in smokers who relapse or quit. Health Psychol. 1987;6(4):289-303.
27. Pomerleau CS. Smoking and nicotine replacement treatment issues specific to women. Am J Health Behav. 1996;20:291-299.
28. Tøttenborg SS, Lange P, Johnsen SP, Nielsen H, Ingebrigtsen T, Thomsen RW. Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD. Respir Med. 2016;119:160-167.
29. Reda AA, Kotz D, Evers SM, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2012;(6):CD004305.
30. Pisinger C, Aadahl M, Toft U, Jorgensen T. Motives to quit smoking and reasons to relapse differ by socioeconomic status. Prev Med. 2011; 52(1):48-52.
31. Schiller JS, Ni H. Cigarette smoking and smoking cessation among persons with chronic obstructive pulmonary disease. Am J Health Promot. 2006;20(5):319-323.
32. van Eerd EAM, Bech Risor M, Spigt M, et al. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. NPJ Prim Care Respir Med. 2017;27(1):41.
33. Blackstock FC, ZuWallack R, Nici L, Lareau SC. Why don’t our patients with chronic obstructive pulmonary disease listen to us? The enigma of nonadherence. Ann Am Thorac Soc. 2016;13(3):317-323.
34. Tottenborg SS, Lange P, Johnsen SP, Nielsen H, Ingebrigtsen TS, Thomsen RW. Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD. Respir Med. 2016;119:160-167.